QC
NBIX icon

Quadrature Capital’s Neurocrine Biosciences NBIX Stock Holding History

Quadrature Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.3M Sell
13,668
-15
-0.1% -$2.23K 0.02% 468
2026
Q1 		$1.8M Buy
+13,683
New +$1.82M 0.02% 410
2025
Q4 		– Sell
-11,376
Closed -$1.6M – 1530
2025
Q3 		$1.6M Sell
11,376
-3,433
-23% -$465K 0.02% 326
2025
Q2 		$1.86M Buy
14,809
+11,162
+306% +$1.28M 0.03% 304
2025
Q1 		$403K Buy
+3,647
New +$462K 0.01% 641

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Quadrature Capital's NBIX Position: Q2 2026 in Review

Quadrature Capital reduced its Neurocrine Biosciences (NBIX) stake by 0.11% in Q2 2026, selling an estimated $2.23K and leaving 13,668 shares worth $2.3M. The position accounts for 0.02% of the portfolio, ranked #468.

Quadrature Capital first reported a position in NBIX in Q1 2025 and has held it in 5 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Quadrature Capital held 13,668 shares of Neurocrine Biosciences worth $2.3M as of Q2 2026.
  • Quadrature Capital sold 15 Neurocrine Biosciences shares in Q2 2026, an estimated $2.23K.
  • Neurocrine Biosciences made up 0.02% of Quadrature Capital's portfolio in Q2 2026, its #468 holding.
  • Quadrature Capital first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 5 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.